

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of

Applicants : Vidler et al.  
Serial No. : 10/822,386  
Filed : April 12, 2004  
Title : DATA CARRIER FOR HEALTH RELATED INFORMATION  
Docket : STD 1222 PA/41213.596  
Art Unit : 3722  
Confirm. No. : 2855

MAIL STOP AMENDMENT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.56, 1.97, AND 1.98

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 CFR §1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 CFR §1.56(a). While the information referred to in this Supplemental Information Disclosure Statement may be material pursuant to 37 CFR §1.56(b), the filing of this Supplemental Information Disclosure Statement is not intended to, pursuant to 37 CFR §1.97(h), constitute an admission that any patent, publication, or other information referred to is, or is considered to be, material to the patentability of this invention. No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103, and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish otherwise. Further, pursuant to 37 CFR §1.97(g), the filing of this Statement should not be construed as a statement that a search has been made or that no other material information exists.

This Supplemental Information Disclosure Statement is filed after the period set forth in §1.97(c) and after the mailing date of a final action under §1.113 or a notice of allowance under §

Serial No. 10/822,386  
Docket No. STD 1222 PA/41213.596

1.311, but before payment of the issue fee, and is accompanied by a Credit Card Payment Form (PTO-2038) in the amount of \$ 180.00 in payment of the required fee set forth in 37 CFR §1.17(p).

The undersigned attorney certifies that no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of the information disclosure statement.

The Office has waived the requirement pursuant to 37 CFR 1.98 (a)(2)(i) for submitting a copy of each cited U.S. patent and each U.S. patent application publication for all U.S. national patent applications filed after June 30, 2003 and for all international applications that have entered the national stage under 35 USC § 371 after June 30, 2003. Therefore, no copies of each cited U.S. patent and each cited U.S. patent application publication are enclosed, but the cited U.S. patents and the cited U.S. patent application publications are listed on PTO/SB/08a.

Respectfully submitted,  
DINSMORE & SHOHL LLP

By /James F. Gottman/  
James F. Gottman  
Registration No. 27,262

One Dayton Centre  
One South Main Street, Suite 1300  
Dayton, Ohio 45402-2023  
Telephone: (937) 449-6400  
Facsimile: (937) 449-6405  
JFG/bab  
Encls.